These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 29703689

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Accuracy of digital mammography, ultrasound and MRI in predicting the pathological complete response and residual tumor size of breast cancer after completion of neoadjuvant chemotherapy.
    Sudhir R, Koppula VC, Rao TS, Sannapareddy K, Rajappa SJ, Murthy SS.
    Indian J Cancer; 2022; 59(3):345-353. PubMed ID: 33753611
    [Abstract] [Full Text] [Related]

  • 23. Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.
    Park S, Yoon JH, Sohn J, Park HS, Moon HJ, Kim MJ, Kim EK, Kim SI, Park BW.
    PLoS One; 2016; 11(2):e0149347. PubMed ID: 26866475
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
    Hayashi N, Tsunoda H, Namura M, Ochi T, Suzuki K, Yamauchi H, Nakamura S.
    Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
    Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE.
    Ann Surg; 2006 Feb; 243(2):257-64. PubMed ID: 16432360
    [Abstract] [Full Text] [Related]

  • 31. Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.
    Murphy C, Mukaro V, Tobler R, Asher R, Gibbs E, West L, Giuffre B, Baron-Hay S, Khasraw M.
    Intern Med J; 2018 Jun; 48(6):699-705. PubMed ID: 28869790
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy.
    Kim SY, Cho N, Park IA, Kwon BR, Shin SU, Kim SY, Lee SH, Chang JM, Moon WK.
    Radiology; 2018 Nov; 289(2):327-334. PubMed ID: 30152744
    [Abstract] [Full Text] [Related]

  • 34. The Accuracy of Mammography, Ultrasound, and Magnetic Resonance Imaging For the Measurement of Invasive Breast Cancer With Extensive Intraductal Components.
    Kim YE, Cha JH, Kim HH, Shin HJ, Chae EY, Choi WJ.
    Clin Breast Cancer; 2023 Jan; 23(1):45-53. PubMed ID: 36328930
    [Abstract] [Full Text] [Related]

  • 35. Value of mammographic microcalcifications and MRI-enhanced lesions in the evaluation of residual disease after neoadjuvant therapy for breast cancer.
    Zhu C, Chen M, Liu Y, Li P, Ye W, Ye H, Ye Y, Liu Z, Liang C, Liu C.
    Quant Imaging Med Surg; 2023 Sep 01; 13(9):5593-5604. PubMed ID: 37711784
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging.
    Iotti V, Ravaioli S, Vacondio R, Coriani C, Caffarri S, Sghedoni R, Nitrosi A, Ragazzi M, Gasparini E, Masini C, Bisagni G, Falco G, Ferrari G, Braglia L, Del Prato A, Malavolti I, Ginocchi V, Pattacini P.
    Breast Cancer Res; 2017 Sep 11; 19(1):106. PubMed ID: 28893303
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment.
    Moon HG, Han W, Lee JW, Ko E, Kim EK, Yu JH, Kang SY, Moon WK, Cho N, Park IA, Oh DY, Han SW, Im SA, Noh DY.
    Ann Oncol; 2009 Apr 11; 20(4):636-41. PubMed ID: 19179551
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.